Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod
19/08/2026 22:24
Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod Aug 19(Reuters) - The U.S. Food and Drug Administration approved Ultragenyx Pharmaceutical's RARE.O gene therapy to treat a rare metabolic disorder, the company said on Wednesday.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Leroy Leo)
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx